<DOC>
	<DOCNO>NCT03019575</DOCNO>
	<brief_summary>The purpose study investigate whether corifollitropin alfa ( MK-8962 ) , administer combination human chorionic gonadotropin ( hCG ) , increase testicular volume adolescent male age 14 &lt; 18 . In addition , study evaluate participant development corifollitropin alfa antibody course 64 week treatment .</brief_summary>
	<brief_title>Efficacy Safety Corifollitropin Alfa ( MK-8962 ) Combination With Human Chorionic Gonadotropin ( hCG ) Adolescent Males With Hypogonadotropic Hypogonadism ( HH )</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Have legal representative understands study procedure , alternative treatment available risk involve study , voluntarily agree individual 's participation give write informed consent , individual ageappropriate understand give inform write assent applicable . Diagnosed hypogonadotropic hypogonadism ( either isolate associated panhypopituitarism ) , either congenital acquire onset prior puberty . Have bilateral pregonadarche testis define testicular volume &lt; 4.0 mL testicle , determine ultrasound assessed investigator ( qualify ) local radiologist appropriate training expertise read testicular ultrasound . Note : participant volume &lt; 4.0 mL one testicle volume 48 mL testicle consider pregonadarche may participate , history evidence primary testicular disorder ( see Exclusion Criteria 1 2 ) . Circulating level total testosterone ( Total T ) less low limit normal ( LLN ) 8.3 nmol/L specify central lab young healthy adult male . Follicle stimulate hormone ( FSH ) ≤2 IU/L luteinizing hormone ( LH ) ≤2 IU/L . InhibinB level ≤35 pg/mL . ( Note : individual inhibinB level &gt; 35 pg/mL , meet inclusion/exclusion criterion , either GnRH agonist ( GnRHa ) stimulation test GnRH IV infusion test may perform . In good general physical mental health , opinion investigator/sponsor , assess physical examination routine clinical laboratory test . Have parent/guardian able willing support individual 's participation support adherence study drug dose visit schedule . History bilateral cryptorchidism ( maldescended testis ) unilateral cryptorchidism treat age 2 year . History presence clinically significant testicular problem ( e.g. , epididymitis , orchitis , testicular torsion , varicocele Grade III , testicular atrophy , occlusive azoospermia , etc . ) would impair participant response treatment know damage injury va deferens . Previous treatment GnRH , gonadotropin ( e.g. , hCG , FSH ) androgens ( e.g. , testosterone , etc. ) . Note : Use GnRH gonadotropins diagnostic testing purpose allow . Participants use hCG androgen therapy prior age 2 year old include trial . Participants transient use androgen ( i.e. , less 2 week ) stop least 6 month prior sign inform consent also include trial . Untreated inadequately treated pituitary hypothalamic tumor . Uncontrolled endocrinopathies , include thyroid , adrenal , pituitary disorder stable replacement therapy . History active pituitary hypersecretion evidence hyperprolactinemia Cushing 's disease , acromegaly , active pituitary hypersecretion syndrome . ( Note : Individuals treat clinically stable , evidence hypersecretion least 12 month prior screen , may participate . Has hypophysectomy within 12 month start screen . History oncologic chemotherapy treatment . Brain radiotherapy within 12 month start treatment primary tumor , history brain radiotherapy metastatic disease . Diabetes mellitus . History Human Immunodeficiency Virus ( HIV ) . Clinically significant liver disease , include active viral hepatitis cirrhosis . Individuals prior history liver disease inactive successfully treat may enrol liver function value perform within past year normal within normal range Visit 1 . Recent history recreational illicit drug use , include marijuana ; routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking . Has allergy/sensitivity gonadotropins its/their excipients . Has use investigational drug and/or participate clinical trial within past 8 week ( prior Visit 2 ) , participate clinical trial ( exclude survey ) course trial .</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>